RESEARCH OVERVIEW – ANTHRACYCLINES

An Italian study published in 2019 assessed the effectiveness of scalp cooling with DigniCap for patients receiving adjuvant chemotherapy with an anthracycline with or without taxanes.

As Published
Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines.
British Journal of Cancer (2019) 121:325-331
Munzone, E, et al.

Summary

  • The DigniCap System was able to prevent significant hair loss in 43% of breast cancer patients receiving adjuvant chemotherapy.
  • The study had a lower than expected dropout rate with only 7% discontinuation. Among the patients that continued, the success rate was 54%.
  • None of the patients who participated in the study using DigniCap developed scalp metastases after a mean follow-up of 2.4 years.
Please note that the content of this website is not intended as professional medical or healthcare advice and should not be construed as a substitute for professional healthcare advice, or services from a qualified professional healthcare provider familiar with your unique situation. This content is intended solely as a general product and corporate information.

OPERATIONS
Dignitana
10925 Estate Lane, Suite 185
Dallas, TX 75238
+1 877-350-2150

HEADQUARTERS
Dignitana AB
Traktorgränden 3
226 60 Lund, Sweden
+46 46 16 30 90

HEADQUARTERS
Dignitana S.r.l.
Corso di Porta Nuova, 46
20121 Milan, Italy